ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals
ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary BioFirst Corporation received a milestone payment of 10M shares of ForSeeCon Eye Corporations securities to which the parties impute a value of $6 per share based on an internal valuation and a cash payment of $196,000 for its global licensing agreement with ForSeeCon Eye Corporation, which is for the Company's Ophthalmology pipeline, including the medical device Vitargus (valued at $187M, by third-party valuer) (the "Licensed Products").
美股ABVC BioPharma, Inc.（纳斯达克：ABVC）宣布，该公司及其子公司BioFirst Corporation已收到ForSeeCon Eye Corporations证券1000万股的里程碑支付，根据内部估值，将其价值计入6美元/股，并获得了196000美元的现金支付。该股权协议为该公司的眼科医疗产品线提供了全球授权，其中包括经过第三方估价为1.87亿美元的医疗器械Vitargus（“许可产品”）.
ForSeeCon Eye Corporation is a private company registered in the British Virgin Islands. With this payment, the Company has now received aggregate cash payments of $296,000 from ForSeeCon and Oncox ($100,000), one of the Companys other licensees.
ForSeeCon Eye Corporation 是在英属维尔京群岛注册的私人公司。该公司目前总计已从ForSeeCon和Oncox公司（100,000美元）-该公司的其他许可证持有方，收到了现金支付296,000美元。
In addition to the cash payment, the Company has already received stocks from AiBtl (another licensee) and ForSeeCon, which the company believes are valued at $460M and $60M, respectively. The Company expects to receive additional stocks from OncoX that the Company believes is valued at $50M,3 up to $23.7M in cash and royalties of up to $370M from net sales from all three licensees (AiBtl, ForSeeCon, and OncoX), although such net sales cannot be guaranteed.
除现金支付外，该公司已收到了AiBtl（另一个持有方）和ForSeeCon的股票，公司认为其价值分别为4.6亿美元和6,000万美元。该公司预计将从OncoX获得额外的股票，该公司认为该股票价值为5,000万至等值美元，并且会收到三家持有方（AiBtl，ForSeeCon和OncoX）的净销售额折扣-额外的23.7万美元的现金，以及折扣收入高达3.7亿美元的版税，尽管不能保证这些净销售额。
"This milestone payment marks a significant achievement in the partnership between ABVC and ForSeeCon. It reflects ForSeeCon's confidence in the Licensed Products and its determination to bring the Licensed Products to market if it completes the remaining clinical trials. It also underscores the progress towards the overall project objectives," said Dr. Uttam Patil, ABVC's Chief Executive Officer.
"这项里程碑支付标志着ABVC和ForSeeCon合作关系的重要成就。它反映了ForSeeCon对许可产品的信心，并决心在完成其余的临床试验后将许可产品推向市场。它也强调了向整体项目目标的进展。"ABVC的首席执行官Uttam Patil博士表示。
He added, "The team is thrilled to receive this milestone payment from its valued partner and expects the remaining $6.8M soon. In addition to the milestone payment, the collaboration between ABVC and ForSeeCon will continue to work on adding more sites for the pivotal study and ramp up the momentum for further development to get Vitargus commercialized."
他补充说:"整个团队都很高兴以所钟爱的合作伙伴获得这项里程碑支付，并预计很快会收到剩余的6.8百万美元。除了里程碑支付外，ABVC和ForSeeCon之间的合作还将继续努力为关键研究增加更多的现场并增加推动Vitargus商业化的势头。"
"It demonstrates the strength of our collaboration and the dedication of both teams to achieving our shared goals. This milestone represents an important step forward in our project and reaffirms our commitment to delivering innovative solutions in the Ophthalmology industry," said Jerry Chang, CEO of ForSeeCon Eye Corporation. He added, "ForSeeCon is also working on getting the Vitargus Pilot plant facility to upgrade and receive the GMP certification."
"这证明了我们团队之间合作的强度和双方都为实现我们共同的目标而努力的决心。"ForSeeCon Eye Corporation的首席执行官Jerry Chang表示。"这个里程碑代表着我们项目向前迈出的重要一步，并重申了我们致力于在眼科医疗行业中提供创新解决方案的承诺。"他补充说:"ForSeeCon Eye Corporation还在努力将Vitargus Pilot工厂设施升级并获得GMP认证。"
Management believes the Company's product pipeline has excellent market potential. According to iHealthcare Analyst, Inc., the global market for retinal surgery devices is expected to reach $4.3 billion by 2029, at a CAGR of 7.7%, driven partly by the rising geriatric population worldwide.
管理层认为，该公司的产品线具有良好的市场潜力。根据iHealthcare Analyst, Inc.的数据，到2029年，视网膜手术设备的全球市场预计将达到43亿美元，年复合增长率为7.7％，部分受全球老龄人口的增长所推动。
ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707
ABVC敦促其股东在公司网站上注册获取最新的新闻警报; 请访问https://abvcpharma.com/?page_id=17707